Effect of Unrestricted Access to Running Wheels on Cancer-Related Fatigue by Little, Courtney







Effect of Unrestricted Access to Running Wheels on Cancer-Related Fatigue 
Courtney R. Little, SN & Donna O. McCarthy, PhD, RN, FAAN 
The Ohio State University 
College of Nursing  
Running head: EFFECT OF WHEEL RUNNING ON CANCER-RELATED FATIGUE 2 
 
Abstract 
Cancer-related fatigue (CRF) occurs in 60-90% of cancer patients and significantly reduces 
functional status.  Tumor growth causes significant wasting of skeletal muscle, thought to be a 
major factor in CRF.  Cancer patients also report depressed mood, contributing to feelings of 
fatigue.   Exercise has been shown to have anti-depressant effects in mice and humans, though its 
effect on tumor-induced muscle wasting has not been studied. The purpose of the study is to 
determine the effect of voluntary wheel running activity (VWRA) on muscle mass and 
depression-like behavior in a mouse model of CRF. In mice, fatigue is modeled as a decline in 
VWRA and depression is modeled as anhedonia, a loss of preference for sucrose solution. 
Twenty adult female, age-matched mice were divided into 4 groups, half having ad libitum 
access to running wheels and half serving as sedentary controls. Half of each group was 
inoculated with tumor cells and half were healthy controls. VWRA, sucrose preference and total 
fluid intake were measured on days 1, 7, 14, and 19 of tumor growth. Mice were euthanized on 
day 21 and the gastrocnemius muscle and spleen were weighed. Unrestricted access to exercise 
wheels did not affect sucrose preference compared with sedentary animals, and there was no 
evidence of anhedonia in tumor-bearing mice. Unrestricted access to exercise wheels did not 
improve muscle mass though VWRA was significantly correlated with muscle mass. Further 
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Statement of the Problem 
Introduction 
Fatigue and depression are two symptoms frequently associated with cancer. They can be 
present during and after cancer treatment for a wide range of tumor types. Cancer related fatigue 
(CRF) is characterized by an excessive sense of tiredness, unaffected by rest or sleep, that 
interferes with daily functioning and quality of life. CRF often co-occurs with depression, but 
can be found in isolation (Minton, Richardson, Sharpe, Hotopf, & Stone, 2008). 
Background 
Cancer-related fatigue (CRF) is a condition characterized by extreme tiredness, 
weakness, and lack of energy (Hofman, Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007). 
Depression is also often associated with CRF (Cella, Davis, Breitbart, & Curt, 2001) This 
symptom cluster can afflict cancer patients at all stages of the disease process, from treatment to 
survivorship (Ryan et al., 2007). Moreover, CRF can last from months to years following 
completion of treatment, and is the most distressing symptom reported by cancer survivors 
(Hofman, et al., 2007). Prevalence of CRF has been reported between 60 and 90% and is a 
significant cause of morbidity (Cella, et al., 2001). The prevalence of CRF is on the rise as the 
use of more aggressive therapies and cancer survivorship also rises. During treatment, CRF can 
cause a delay in chemotherapy administration, impede adherence to treatment regimens, or affect 
the dose of chemotherapy that can be given due to the severity of fatigue experienced by the 
patient (Hofman, et al., 2007). 
The underlying mechanisms of CRF are poorly understood, which makes it even more 
difficult to discern the cause. Proinflammatory cytokines, namely interleukin-1beta (IL-1β), 
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interleukin-6 (IL-6), and TNF-α have been implicated in the development of skeletal muscle 
wasting and depressed mood, both of which are thought to contribute to CRF. Pro-inflammatory 
cytokines are produced either by the tumor or as a host response to tumor growth. In muscle, 
cytokines activate mechanisms causing hypoanabolism and hypercatabolism, which causes 
muscle wasting or loss of lean body mass. Furthermore, TNF-α and IL-6, are thought to 
contribute to weight loss and skeletal muscle wasting, also called cachexia, in persons with 
advanced cancer (Wang, 2008).  
There is also increasing evidence linking chronic inflammation and pro-inflammatory 
cytokines with depression (Capuron et al., 2002). In animal models, administration of the 
endotoxin, lipopolysaccharide (LPS), has been shown to increase cytokine production and induce 
“sickness behavior,” which includes anhedonia, the inability to experience pleasure, and reduced 
physical activity. The presence of these cytokines leads to alterations in the production of 
serotonin and serotonin transporters in brain areas important in the regulation of mood and 
activity (Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008). In rodents, anhedonia is 
modeled as decreased preference for sweetened water or milk.  
Clinicians are in agreement that depressed mood is often present in patients with CRF, 
though it is not known if treatment of depression would reduce the severity of fatigue. 
Conversely, lack of energy and reduced physical activity are a significant component of 
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Purpose 
The purpose of this study is to determine if physical activity, modeled as unrestricted 
access to running wheels, will affect mood and muscle mass in tumor-bearing mice. In mice, 
depressed mood is modeled as a reduced preference for sucrose solution. Fatigue is modeled as a 
decrease in voluntary wheel running activity (VWRA). We expect to observe: 
1. Increased sucrose preference in tumor-bearing mice that have unrestricted access to 
running wheels when compared to sedentary mice. 
2. Increased VWRA in tumor-bearing mice that have unrestricted access to running wheels 
when compared to sedentary mice 
3. Increased muscle mass in mice with unrestricted access to running wheels compared to 
sedentary controls. 
Significance 
CRF is a debilitating experience for cancer patients. As fatigue has no one defined 
etiology and no targeted treatments, it often is unrecognized and undertreated. CRF can 
significantly impact the financial and social burden of cancer treatment and management. If 
exercise can improve mood and reduce skeletal muscle wasting, it may be effective in reducing 
CRF. 
Review of Literature 
CRF is defined as overwhelming tiredness, weakness, and lack of energy. These 
symptoms can significantly reduce quality of life, impair functional status, alter social roles, and 
cause significant financial burden. CRF is composed of both a central component and a 
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peripheral component. Centrally, fatigue is the result of changes in the hypothalamic-pituitary-
adrenal (HPA) axis and neuronal systems controlling arousal and activity. Peripherally, fatigue is 
the result of alterations in skeletal muscle function (Narayanan & Koshy, 2009).  
A significant component of peripheral fatigue in cancer patients is skeletal muscle 
wasting. Skeletal muscle wasting is the result of an imbalance between protein synthesis and 
protein catabolism. The inflammatory response to tumor growth stimulates protein degradation 
pathways which lead to protein catabolism and loss of skeletal muscle mass. Muscle function is 
proportional to muscle mass in both humans and mice (Weber et al., 2009; Gorselink et al., 
2006). A study by Diffee, et al. (2002) demonstrated that tumor-bearing mice had changes in 
myosin heavy chain type I and II proteins in the soleus muscle which would affect objective 
muscle function and resistance to fatigue.  
CRF often co-occurs with depressed mood, which reduces motivation to engage in 
physical activity. The subsequent decrease in physical activity could contribute to additional loss 
of muscle mass, further reducing skeletal muscle function. Fatigue is often worse in patients that 
also experience depressed mood (Kuhnt et al., 2009). Animal models have been used to 
demonstrate that acute and chronic activation of the immune system leads to “sickness 
behavior,” characterized by lethargy and depressed mood. While lethargy resolves spontaneously 
after a few days of immune activation, depressive symptoms such as anhedonia persist (Moreau 
et al., 2008). In one study, animals exhibiting sickness behavior after LPS administration showed 
no anhedonia when given the tricyclic antidepressant imipramine (Dunn, Swiergiel, & de 
Beaurepaire, 2005). Furthermore, the symptoms of “sickness behavior” closely mirror depressive 
behaviors exhibited by cancer patients. Thus, measuring anhedonia can be an effective method to 
differentiate between fatigue and depressive behaviors.  
Running head: EFFECT OF WHEEL RUNNING ON CANCER-RELATED FATIGUE 7 
 
Studies using animal models have clearly shown that proinflammatory cytokines such as 
IL-1β, IL-6, and TNF-α are involved in the onset of sickness behaviors (De La Garza, 2005). 
Depressive behaviors have been linked with increased expression of pro-inflammatory cytokines 
in the brain, as well as 2,3-indolamine oxygenase (IDO) (O’Connor et al., 2009). IDO is a 
competitive antagonist to serotonin synthesis, and reduces the conversion of tryptophan to 
serotonin. Serotonin is a neurotransmitter implicated in both mood regulation and locomotor 
activity. Pro-inflammatory cytokines also reduce serotonin activity in the brain by increasing the 
activity of serotonin transport proteins (Zhu, Blakely, & Hewlett, 2006; Su et al., 2009; Muller & 
Schwartz, 2007; Harden, du Plessis, Poole, & Laburn, 2006). However, drugs that increase 
serotonin activity in the brain, such as selective serotonin re-uptake inhibitors, do not reduce 
fatigue in cancer patients (Minton, et al., 2008; Breitbart & Alici, 2008). 
In muscle, IL-1β, IL-6, and TNF-α activate the signaling pathways implicated in myosin 
degradation. TNF-α activates NF-kB, which increases muscle expression of MAFbx and 
MuRF1, two E3 ligases in the ubiquitin-proteasome pathway of myosin protein degradation 
(Acharyya & Guttridge, 2007; Acharyya et al., 2004). TNF-α also increases expression of Bnip3, 
which is implicated in the lysosome-mediated autophagy of cell organelles (Saini, Faulkner, Al-
Shanti & Stewart, 2009; Zhao, Brault, Schild, & Goldberg, 2008). Proteolysis Inducing Factor 
(PIF) has been shown to come directly from the tumor cells, and also to contribute to decreased 
protein synthesis and protein degradation in skeletal muscle (Tisdale, 2004). While these 
findings implicate TNF-α in skeletal muscle wasting in cancer patients, agents that block TNF-α 
activity have not demonstrated effectiveness at maintaining lean body mass or reducing fatigue 
in patients with cancer cachexia (Jatoi et al., 2009). 
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TNF-α also increases expression of COX-2 through activation of NF-kB, which has been 
associated with increased skeletal muscle wasting. Non-steroidal anti-inflammatory drugs 
(NSAIDs), which  inhibit both COX-1 and COX-2, have been shown to reduce muscle wasting 
and expression of MAFbx, MuRF1, and type 1 TNF-α receptor in tumor-bearing mice (Graves, 
Ramsay & McCarthy, 2006; Hitt, Graves & McCarthy, 2005). Another study showed that COX 
inhibition reduced depressive behaviors in mice injected with lipopolysaccharide (LPS) without 
reducing expression of pro-inflammatory cytokines in the brain (Teeling, Cunningham, Newman 
& Perry, 2010; Teeling et al., 2007). More research is needed to better understand the 
contribution of COX to sickness symptoms associated with increased cytokine activity. 
There is mounting evidence demonstrating that aerobic exercise has both antidepressant 
and anti-inflammatory qualities. Skeletal muscle produces IL-6 during exercise, which can 
reduce IL-1β and TNF-α (Wood, Nail, & Winters, 2009). Chronic exercise has been shown to 
improve depressive behaviors in rats exposed to uncontrollable stress (Greenwood et al., 2003). 
Duman, Schlesinger, Russell & Duman (2008) demonstrated that mice with free access to 
running wheels showed decreased depression-like behaviors in the forced swim test and the tail 
suspension test. Hoffman-Goetz, Pervaiz, Packer, & Guan (2010) found that healthy mice with 
free access to running wheels showed a reduction in intestinal lymphocyte TNF-α, and an overall 
increase in serum levels of IL-10 and IL-6 compared to sedentary mice. 
Aerobic exercise has also been shown to improve cognitive function and reduce 
depressive symptoms in animals and humans (Churchill et al., 2002; Daley et al., 2007; Segar et 
al., 1998). Similarly, several studies have shown that exercise improves quality of life during 
cancer treatment and reduces the subjective experience of fatigue (Velthius, Agasi-Idenberg, 
Aufdenkampe, & Wittink, 2009; Wood, et al., 2009; Spence, Heesch, & Brown, 2010). 




The study employed a quantitative experimental design with random assignment to 
conditions (tumor, wheels). Tumor growth was induced using the Lewis Lung carcinoma cell 
line. The tumor cells were injected between the scapulae to reduce the likelihood that tumor 
growth would affect mobility. In the LLC model of tumor-induced muscle wasting, progressive 
tumor growth does not suppress food or fluid intake until the mice become moribund, typically 
between 21 to 24 days of tumor growth. The study tested the hypothesis that unrestricted access 
to running wheels will improve VWRA, sucrose preference and skeletal muscle mass in tumor-
bearing mice. The research subjects were 20 age-matched C57Bl/6 female mice. Female mice 
were chosen for this study because female mice run more than male mice. The subjects were 
placed into four groups: no tumor/no wheels, tumor/no wheels, tumor/wheels, no tumor/wheels. 
All procedures were approved by the Institutional Animal Care and Use Committee. 
Voluntary Wheel Running Activity 
Healthy mice normally run on wheels for 2-3 miles a night, and demonstrate reduced 
VWRA as a result of acute or chronic activation of the immune or inflammatory response, or 
tumor growth. (Skinner, et al., 2009; Wood, et al., 2006). With tumor growth, mice run for 
shorter periods of time with increasing time between running episodes, resulting in reduced 
overall wheel revolutions. In the present study, VWRA was measured over 18 hours, including 
the nocturnal phase of activity at baseline (day 0) and on days 7, 14, and 19 of tumor growth. 
Running was measured using the Columbus Instruments Mouse Home Cage Running Wheels 
shown in Figure 1. Each wheel had a magnetic indicator connected to a wheel counter which is 
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connected to a personal computer. Software provided by Columbus Instruments was used to 
define intervals and time frames to measure VWRA. The magnetic sensor counted each wheel 
turn which was then stored cumulatively in the computer software by interval. Wheels were 
suspended in the cages under the wire food and water holder.  
Figure 1. 
 
Retrieved from http://www.colinst.com/brief.php?id=47 7 April 2011 
Sucrose Preference Test 
In rodents, depressed mood is modeled as anhedonia, reduced interest in pleasurable 
activity, measured as a reduced intake of palatable substances, such as sucrose pellets or 
sweetened milk (Yirmiya, 1996). Ideally, animals with access to both nutritive substances, such 
as food and water, and palatable substances will choose the palatable substance even when 
nutrition and fluid requirements are already met (De La Garza, 2005). Sucrose preference was 
used to measure anhedonia and was tested at baseline (day 0), and on days 7, 14, and 19 of tumor 
growth. 
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On the day of testing, water bottles were replaced with two 50mL tubes, one containing 
water obtained from the animal care facility, and one containing 3% sucrose solution. Sucrose 
intake and water intake were measured the following morning. Each bottle was weighed before 
and after the test period and sucrose preference was calculated using the following formula:  
   
                               
                      
 
Procedure 
All mice were housed individually, and acclimated to the cage environment and presence 
of running wheels for 1 week. Mice that did not demonstrate a stable pattern of nocturnal 
running were removed from the experiment. On day 0 of the experiment, baseline VWRA, food 
intake, total fluid intake, and intake of sucrose solution were measured. Upon completion of 
baseline testing, running wheels were removed from the sedentary (no wheels) group of mice. 
Half of the mice in the sedentary and running groups were injected between the scapulae 
with 0.2mL saline containing 5 x 10
5
 Lewis Lung Carcinoma (LLC) cells obtained from 
American Type Tissue Culture (Manassas, VA, USA) and half were injected with 0.2mL of 
normal saline solution. Animals that did not have palpable tumors by day 9 were removed from 
the experiment. VWRA, sucrose preference, and food and fluid intake were measured on days 7, 
14, and 19. On the day of testing, wheels were placed in the cages of sedentary mice. Water 
bottles were replaced with two 50mL tubes with rubber stoppers and sippers. One tube contained 
normal animal care facility water, and one contained 3% sucrose solution. SP and VWRA were 
measured from 4pm to 10am. Mice were euthanized on day 21 of tumor growth followed by 
cervical dislocation. The gastrocnemius muscle and spleen were removed, wrapped in foil, flash-
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frozen in liquid nitrogen and stored at -80°C. To account for variations in body size between 
subjects, gastrocnemius muscle mass was determined by calculating the average of the right and 
left gastrocnemius muscle and dividing by body weight. VWRA is reported as mean wheel count 
per day. To account for differences in VWRA for any given mouse, mean change in VWRA 
between baseline and day 7, day 7 and day 14, and day 14 and day 19 was also determined. 
Data Analysis 
The independent variables were tumor and unrestricted access to running wheels. The 
dependent variables were muscle mass, VWRA, change in VWRA, and SP. Data were first 
analyzed for means and standard deviations among the 4 groups. A two-way (tumor, wheels) 
analysis of variance (ANOVA) was used to test effects of the independent variable on each 
dependent variable. Bivariate correlations were used to examine relationships between dependent 
variables. A probability of less than .05 was considered statistically significant. 
Results 
Tumor growth had a significant effect on relative gastrocnemius muscle mass (p<.001), 
but there was no effect of unrestricted access to running wheels on muscle mass. Spleen size was 
significantly greater in the tumor-bearing mice compared to non-tumor-bearing mice (p=.029), 
confirming the presence of a systemic inflammatory response in tumor-bearing mice, but was not 
affected by access to running wheels (p=.955). Mean spleen weight, muscle mass and VWRA of 
day 19 for each of the 4 groups is shown in Table 1. Neither tumor growth nor unrestricted 
access to running wheels had an effect on VWRA measured on days 7, 14, or 19. However, 
when VWRA was evaluated in terms of net change, a significant decrease occurred between day 
14 and 19 in the tumor group (p=.004), but not in the treatment group.  
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Relative mass of the gastrocnemius muscle was inversely correlated with spleen mass 
(r=-.717, p=.001) indicating that inflammation has a negative effect on muscle mass. Spleen 
mass was also negatively correlated with running on day 19 of tumor growth (r=-.537; p=.018). 
There was no correlation between VWRA on day 19 and muscle mass. 
There were no tumor or treatment effects on sucrose preference (SP). Furthermore, SP on 
day 19 was not correlated with spleen weight or muscle mass. Similarly, no significant 
correlations were observed between SP on any test day and spleen weight or muscle mass. 
Correlations are shown in Table 2. 
Table 1. 






Rel. Gastr Spleen VWRA19 SP19 
Rel. Gastr 
 
1 -.717* .432  -.170  
Spleen 
 
 1 -.537* .074 
VWRA19 
 
  1 -.393  
SP19 
 
   1 







Spleen Weight (g) 
(SD) 
Tot. Wheel Running 19 
(SD) 
Tumor 6 4.97 (0.58) 369.50 (217.29) 1568.67 (1952.07) 
Tumor+Treatment 6 5.03 (0.35) 232.83 (98.29) 1048.40 (1216.43) 
Control 4 6.10 (0.19) 102.25 (11.11) 1172.75 (850.14) 
Control+Treatment 3 5.81 (0.11) 93.00 (9.85) 2895.50 (2423.85) 
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Summary, Conclusions, Findings 
In summary, the study confirmed that tumor growth causes a systemic inflammatory 
response, as demonstrated by greater spleen mass size in tumor vs. control groups. The study 
found tumor growth also causes a significant reduction in skeletal muscle mass when compared 
to healthy controls. Tumor growth also caused a significant decrease in VWRA from day 14 to 
day 19, supporting wheel running as a model for CRF. The study did not demonstrate that 
unrestricted access to running wheels affected muscle mass, VWRA, a measure of fatigue, or SP, 
a measure of anhedonia. 
Discussion 
In the present study, growth of the LLC tumor in mice caused a systemic inflammatory 
response, indicated by an enlarged spleen in the tumor-bearing mice. Tumor growth also caused 
a significant reduction in muscle mass and VWRA in the tumor-bearing mice compared to age-
matched healthy controls. However, we did not observe an effect of tumor growth on sucrose 
preference at any time point tested. 
Unrestricted access to running wheels did not affect muscle mass, VWRA or SP in 
tumor-bearing or healthy control mice. However, an effect may not have been detected due to the 
small sample size of only 12 tumor-bearing mice and 7 healthy controls. Furthermore, SP testing 
was concurrent with testing of VWRA. In mice, running has antidepressive effects, and thus 
measuring VWRA and SP simultaneously could confound SP. Another consideration is that SP 
was tested using a 3% sucrose solution. Since C57 mice are sensitive to sweet taste, this 
concentration may be too high (Sclafani, 2005). 
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There was a very wide variation in wheel counts among all groups. While the study was 
able to demonstrate a relationship between decline in VWRA and tumor growth by comparing 
the change in running between days 14 and 19, there was no relationship between mice with 
unrestricted access to running wheels and healthy controls.  
In summary, Hypothesis 1 was not confirmed as the present study was unable to 
demonstrate a difference in sucrose preference between tumor-bearing mice and healthy controls. 
Moreover, there was no difference in sucrose preference between sedentary mice and mice with 
unrestricted access to running wheels. Hypothesis 2 was not confirmed as there was no 
difference in VWRA between sedentary mice and those with unrestricted access to wheels. 
Hypothesis 3 was not confirmed because there was no significant difference of muscle mass 
between the sedentary mice and those with unrestricted access to running wheels. More studies 
are needed to determine if aerobic activity will preserve muscle mass, reduce fatigue and 
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